Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(10):1582–1587. doi: 10.1038/sj.bjc.6690566

Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans

T B Christensen 1,4, J Marqversen 2, F Engbaek 3, P Berger 5, T Bacher 2, H von der Maase 1
PMCID: PMC2363111  PMID: 10408403

Abstract

We have recently introduced 125I-hCG as an elimination marker in patients with human chorionic gonadotrophin (hCG) producing testicular cancer. 125I-hCG is a well-known reagent in clinical biochemistry and is used extensively in hCG assays. Previous studies have shown that the iodination process leaves the hCG molecule mainly intact. The iodination, purification and stability of 125I-hCG tracer are described. The aim of the present study was to determine whether or not 125I is associated with hCG after the injection of 125I-hCG intravenously (i.v.) in humans. Three different methods were used. Following injection of 125I-hCG, the plasma disappearance of radioactivity and hCG were followed for a period of 28 days in 13 normal subjects. Serum from a normal healthy male following injection of 125I-hCG was analysed using a double antibody direct binding radioimmunoassay specific for holo-hCG and high performance liquid chromatography (HPLC). Following injection of 125I-hCG in eight normal healthy males and five normal healthy females, the disappearance of radioactivity and hCG showed identical paths in the 28 days follow-up period. The bindable radioactive fraction of immunologically active hCG in serum of a normal healthy male following injection of 125I-hCG was between 57.0% and 72.1%, and was constant over time. HPLC showed similar elution pattern of serum from a normal healthy male injected i.v. with 125I-hCG and 125I-hCG. Using three different methods, we were able concurrently to demonstrate the association of 125I with hCG in humans up to 28 days after injection of radiolabelled hCG i.v. Thus, information about the expected elimination of hCG can be obtained by following the elimination of activity in plasma after injection of 125I-hCG. © 1999 Cancer Research Campaign

Keywords: gonadotropins, human chorionic, radioiodinated hCG, in vivo elimination

Full Text

The Full Text of this article is available as a PDF (110.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger P., Panmoung W., Khaschabi D., Mayregger B., Wick G. Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiomometric assay. Endocrinology. 1988 Nov;123(5):2351–2359. doi: 10.1210/endo-123-5-2351. [DOI] [PubMed] [Google Scholar]
  2. Bosl G. J., Chaganti R. S. The use of tumor markers in germ cell malignancies. Hematol Oncol Clin North Am. 1994 Jun;8(3):573–587. [PubMed] [Google Scholar]
  3. Bosl G. J., Head M. D. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors. Int J Biol Markers. 1994;9(1):25–28. doi: 10.1177/172460089400900105. [DOI] [PubMed] [Google Scholar]
  4. Bosl G. J., Lange P. H., Nochomovitz L. E., Goldmann A., Fraley E. E., Rosai J., Johnson K., Kennedy B. J. Tumor markers in advanced nonseminomatous testicular cancer. Cancer. 1981 Feb 1;47(3):572–576. doi: 10.1002/1097-0142(19810201)47:3<572::aid-cncr2820470324>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  5. Catt K. J., Dufau M. L., Tsuruhara T. Radioligand-receptor assay of luteinizing hormone and chorionic gonadotropin. J Clin Endocrinol Metab. 1972 Jan;34(1):123–132. doi: 10.1210/jcem-34-1-123. [DOI] [PubMed] [Google Scholar]
  6. Christensen T. B., Engbaek F., Marqversen J., Nielsen S. I., Kamby C., von der Maase H. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer. 1999 Jul;80(10):1577–1581. doi: 10.1038/sj.bjc.6690565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dirnhofer S., Madersbacher S., Bidart J. M., Ten Kortenaar P. B., Spöttl G., Mann K., Wick G., Berger P. The molecular basis for epitopes on the free beta-subunit of human chorionic gonadotrophin (hCG), its carboxyl-terminal peptide and the hCG beta-core fragment. J Endocrinol. 1994 Apr;141(1):153–162. doi: 10.1677/joe.0.1410153. [DOI] [PubMed] [Google Scholar]
  8. Liu L., Southers J. L., Cassels J. W., Jr, Banks S. M., Wehmann R. E., Blithe D. L., Chen H. C., Nisula B. C. Structure-kinetic relationships of choriogonadotropin and related molecules. Am J Physiol. 1989 Jun;256(6 Pt 1):E721–E724. doi: 10.1152/ajpendo.1989.256.6.E721. [DOI] [PubMed] [Google Scholar]
  9. Markkanen S., Töllikkö K., Jäskeläinen K., Rajaniemi H. Effect of radioiodination on the structural integrity, receptor and antibody-binding activity and circulatory behavior of human choriogonadotropin. Horm Res. 1980;12(1):32–45. doi: 10.1159/000179103. [DOI] [PubMed] [Google Scholar]
  10. Motzer R. J., Gulati S. C., Crown J. P., Weisen S., Doherty M., Herr H., Fair W., Sheinfeld J., Sogani P., Russo P. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer. 1992 Jan 15;69(2):550–556. doi: 10.1002/1097-0142(19920115)69:2<550::aid-cncr2820690245>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  11. Motzer R. J., Mazumdar M., Gulati S. C., Bajorin D. F., Lyn P., Vlamis V., Bosl G. J. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993 Nov 17;85(22):1828–1835. doi: 10.1093/jnci/85.22.1828. [DOI] [PubMed] [Google Scholar]
  12. Murphy B. A., Motzer R. J., Mazumdar M., Vlamis V., Nisselbaum J., Bajorin D., Bosl G. J. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer. 1994 May 15;73(10):2520–2526. doi: 10.1002/1097-0142(19940515)73:10<2520::aid-cncr2820731012>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  13. Toner G. C., Geller N. L., Tan C., Nisselbaum J., Bosl G. J. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 1990 Sep 15;50(18):5904–5910. [PubMed] [Google Scholar]
  14. Wehmann R. E., Nisula B. C. Renal clearance rates of the subunits of human chorionic gonadotropin in man. J Clin Endocrinol Metab. 1980 Apr;50(4):674–679. doi: 10.1210/jcem-50-4-674. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES